<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7608025</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6790</journal-id>
<journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id>
<journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id>
<journal-title-group>
<journal-title>Psychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0033-3158</issn>
<issn pub-type="epub">1432-2072</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28265716</article-id>
<article-id pub-id-type="pmc">5420464</article-id>
<article-id pub-id-type="doi">10.1007/s00213-017-4556-2</article-id>
<article-id pub-id-type="manuscript">NIHMS857864</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Don’t stress about CRF: Assessing the translational failures of CRF<sub>1</sub> antagonists</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Spierling</surname>
<given-names>Samantha R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zorrilla</surname>
<given-names>Eric P.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA</aff>
<author-notes>
<corresp id="FN1"><bold>Correspondence should be addressed to:</bold> Samantha Spierling (<email>samspier@scripps.edu</email>) or Eric P. Zorrilla (<email>ezorrilla@scripps.edu</email>), Committee on the Neurobiology of Addictive Disorders, SP30-2400, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037 USA, Phone: 858-784-8026 (SS) or 858-784-7416 (EPZ), Fax: 858-784-7405</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2018</year>
</pub-date>
<volume>234</volume>
<issue>9-10</issue>
<fpage>1467</fpage>
<lpage>1481</lpage>
<!--elocation-id from pubmed: 10.1007/s00213-017-4556-2-->
<abstract>
<sec id="S1">
<title>BACKGROUND</title>
<p id="P1">Dr. Athina Markou sought treatments for a common neural substrate shared by depression and drug dependence. Antagonists of corticotropin-releasing factor (CRF) receptors, a target of interest to her, have not reached the clinic despite strong preclinical rationale and sustained translational efforts.</p>
</sec>
<sec id="S2">
<title>METHODS</title>
<p id="P2">We explore potential causes for the failure of CRF<sub>1</sub> antagonists and review recent findings concerning CRF-CRF<sub>1</sub> systems in psychopathology.</p>
</sec>
<sec id="S3">
<title>RESULTS</title>
<p id="P3">Potential causes for negative outcomes include: 1) poor safety and efficacy of initial drug candidates due to bad pharmacokinetic and physicochemical properties 2) specificity problems with preclinical screens, 3) the acute nature of screens vs late-presenting patients, 4.) positive preclinical results were limited to certain models and conditions with dynamic CRF-CRF<sub>1</sub> activation not homologous to tested patients, 5) repeated CRF<sub>1</sub> activation-induced plasticity that reduces the importance of ongoing CRF<sub>1</sub> agonist stimulation, 6) therapeutic silencing may need to address CRF<sub>2</sub> receptor or CRF-BP molecules, constitutive CRF<sub>1</sub> activity, or molecules that influence agonist-independent activity or to target structural regions other than the allosteric site bound by all drug candidates We describe potential markers of activation towards individualized treatment, human genetic and functional data that still implicate CRF<sub>1</sub> systems in emotional disturbance, sex differences, and suggestive clinical findings for CRF<sub>1</sub> antagonists in food craving and CRF-driven HPA-axis overactivation.</p>
</sec>
<sec id="S4">
<title>CONCLUSION</title>
<p id="P4">The therapeutic scope of selective CRF<sub>1</sub> antagonists now appears narrower than had been hoped. Yet, much remains to be learned about CRF’s role in the neurobiology of dysphoria and addiction and the potential for novel anti-CRF therapies therein.</p>
</sec>
</abstract>
<kwd-group>
<kwd>CRF or CRH or corticotropin-releasing hormone or corticotropin-releasing factor or CRF1 receptor antagonist or CRH1 receptor antagonist</kwd>
<kwd>drug addiction or alcoholism or alcohol dependence or alcohol use disorder or binge drinking or binge eating or food addiction</kwd>
<kwd>major depression</kwd>
<kwd>generalized anxiety disorder or panic disorder or post-traumatic stress disorder</kwd>
<kwd>antidepressant or anxiolytic</kwd>
<kwd>irritable bowel syndrome</kwd>
<kwd>translation or clinical trial or treatment</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>